Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 161 to 170 of 369 total matches.

Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025  (Issue 1722)
AND LACTATION — No adequate data on vadadustat use in pregnant women are available. Administration of the drug ...
The FDA has approved the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) vadadustat (Vafseo – Akebia) for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least 3 months. Vadadustat is the second HIF-PHI to be approved in the US for this indication; daprodustat (Jesduvroq) was approved earlier, but it was withdrawn from the US market in 2024 for commercial reasons.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):27-9   doi:10.58347/tml.2025.1722b |  Show IntroductionHide Introduction

Lurbinectedin (Zepzelca) for Small-Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
during treatment and for 4 months after the last dose. No data are available on the effects ...
The alkylating agent lurbinectedin (Zepzelca – Jazz) has received accelerated approval from the FDA for treatment of metastatic small-cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy. Accelerated approval was based on the overall response rate and duration of response. About 13-15% of lung cancers are small-cell cancers. Most SCLCs occur in patients who are current or former smokers.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e198-9 |  Show IntroductionHide Introduction

Olutasidenib (Rezlidhia) for Acute Myeloid Leukemia (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
death and altered fetal growth. There are no data on the presence of olutasidenib in human breast milk ...
Olutasidenib (Rezlidhia – Rigel), an oral isocitrate dehydrogenase-1 (IDH1) inhibitor, has been approved by the FDA for treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible IDH1 mutation. It is the second drug that targets cancer metabolism to be approved for this indication; ivosidenib (Tibsovo) was approved in 2022.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e58-9   doi:10.58347/tml.2023.1673e |  Show IntroductionHide Introduction

In Brief: A New Indication for Pemigatinib (Pemazyre) (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
. There are no data on the presence of pemigatinib in human breast milk or its effects on the breastfed infant ...
The oral kinase inhibitor pemigatinib (Pemazyre – Incyte) has been approved by the FDA for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. It is the first targeted therapy to be approved in the US for this indication. The drug received accelerated approval from the FDA in 2020 for treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or other rearrangements.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e71-2   doi:10.58347/tml.2023.1674g |  Show IntroductionHide Introduction

Eflornithine (Iwilfin) for High-Risk Neuroblastoma (online only)

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
after the last dose. No data are available on the presence of eflornithine in human breast milk or its ...
Eflornithine (Iwilfin – US WorldMeds), an oral ornithine decarboxylase inhibitor, has been approved by the FDA to reduce the risk of relapse in children and with high-risk neuroblastoma who had at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy. About 40-50% of neuroblastoma cases are classified as high-risk and they account for ~15% of all pediatric cancer deaths. Eflornithine is the first drug to be approved to reduce the risk of relapse in children with high-risk neuroblastoma. Eflornithine was previously available in the US...
Med Lett Drugs Ther. 2024 May 13;66(1702):e81-2   doi:10.58347/tml.2024.1702f |  Show IntroductionHide Introduction

In Brief: A New Indication for Tenecteplase (TNKase)

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
, with higher scores indicating greater disability) 90–120 days after treatment. At the time of data cutoff ...
The tissue plasminogen activator (tPA) tenecteplase (TNKase – Genentech) has been approved by the FDA for treatment of acute ischemic stroke in adults. It is the second tPA to be approved in the US for this indication; alteplase (Activase) was approved in 1996. Tenecteplase was approved in 2000 to reduce the risk of death associated with acute ST-elevation myocardial infarction (STEMI).
Med Lett Drugs Ther. 2025 Apr 28;67(1727):71-2   doi:10.58347/tml.2025.1727d |  Show IntroductionHide Introduction

Drugs for Alcohol Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021  (Issue 1639)
intellectual disability, and alcohol spectrum disorders in the offspring. Data on the use of drugs for AUD ...
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 in the past year. The lifetime prevalence of AUD in the US population has been estimated to be about 30%. Despite this high prevalence and the associated morbidity, mortality, and costs, only 3 drugs are FDA-approved for treatment of the disorder.
Med Lett Drugs Ther. 2021 Dec 13;63(1639):193-8 |  Show IntroductionHide Introduction

Ashwagandha Supplements

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
has been reported to cause miscarriage; it should not be used during pregnancy. No data are available ...
Ashwagandha is an herb extracted from the roots of an evergreen shrub (Withania somnifera) found in India that has been used as a "tonic" for centuries. No specific constituent has been identified as an active ingredient. Herbal supplements containing ashwagandha, which is also known as winter cherry and Indian ginseng, are widely promoted now in the US for treatment of pain, anxiety, stress, fatigue, sleep disturbances, cognitive decline, diabetes, arthritis, male infertility, and various cancers.
Med Lett Drugs Ther. 2021 Mar 8;63(1619):39-40 |  Show IntroductionHide Introduction

Fluvoxamine for COVID-19?

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
-19, but conclusive data supporting its use are lacking. A large trial is underway. 1. Treatments ...
A recent article in JAMA and an interview of its senior author on 60 Minutes have heightened interest in off-label use of the oral selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Luvox, and generics) to treat COVID-19.
Med Lett Drugs Ther. 2021 May 3;63(1623):69-70 |  Show IntroductionHide Introduction

Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) for Prostate Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
(PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Data on efficacy of the drug ...
The FDA has approved lutetium lu 177 vipivotide tetraxetan (Pluvicto – Novartis) for treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adults previously treated with androgen receptor (AR) pathway inhibitors and taxane-based chemotherapy.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e207-8 |  Show IntroductionHide Introduction